Gsk Share Discussion Threads

[fangorn2] 23/7/2018 09:35

" Personally I believe if you can't afford the FT, or for some reason don't want to pay, you are not serious enough, or don't have the capital, to be an investor."

How pretentious.

[garycook] 23/7/2018 09:29

What happened to the predicted 3/4% rise in GSK this morning ?

[minerve] 23/7/2018 09:23

Actually the real reason is Losos doesn't want to pay the FT subscription. He is too busy practising anthropomorphism - buying little outfits for his dogs and treating them like human babies - to have any money left for a c£350 subscription. Personally I believe if you can't afford the FT, or for some reason don't want to pay, you are not serious enough, or don't have the capital, to be an investor.

It is like a doctor not having a stethoscope. I actually gauge the weight of other investors by whether they subscribe to the FT. I don't give non-FT subscribers much weight. It doesn't show commitment of confidence towards their investing IMO.

There are exceptions, but they are few.

[scotches] 23/7/2018 08:10

>>>the articles were behind the pay wall.

"GSK board considers break-up of group"

"Emma Walmsley plots course out of ‘hobbylandR17; for GSK"

You can avoid the FT paywall by copying article titles into google and then accessing FT from the google link. This jumps the paywall.

This trick has worked for several years but doesn't apply to certain premium FT content like the Lex column.

[pugugly] 23/7/2018 07:50

Just a small advance from pharma but very useful and creat of publicity and awareness of GSK in the malaria areana.

The approval of Krintafel [the brand name for tafenonquine], the first new treatment for Plasmodium vivax malaria in over 60 years, is a significant milestone for people living with this type of relapsing malaria.

[zho] 23/7/2018 07:28

Losos - sorry about that - I could read the articles okay (although I am signed up for the FT's free content) but when I tried again the articles were behind the pay wall.

[losos] 22/7/2018 20:32

zho - thanks for those links, in my case they are both behind some kind of 'pay wall' but you tried. I could maybe go for their 'trial period' offer but I am becomming more and more reluctant to 'register' with media companies now, even if free, my personal data is something I value and don't want to be bombarded by e-mails let alone have some scumbag hack into the FT and steal the data. Everyone thinks it can't happen but there have been too many data breaches for my liking.

[zho] 22/7/2018 09:25

These articles don't appear to be behind the FT's paywall:


GlaxoSmithKline’s chairman is weighing the merits of splitting up the company after several top-10 investors pressed the board to consider spinning off the UK pharma group’s consumer division.




When Emma Walmsley vowed that UK drugmaker GlaxoSmithKline would no longer drift off into “ hobbyland” and develop drugs without obvious commercial potential, the frank language from the company’s new chief executive took some observers by surprise.

[ianood] 22/7/2018 08:54

Poikka, I agree with you entirely. It looks to me to be much more of a balanced discussion than an instruction.

[poikka] 21/7/2018 21:40

Is Hampton really overruling EW? As far as I can see, all he's doing is responding to some shareholders, and hopefully EW's busy doing the real stuff. Has he given an opinion? Does anybody know EM's take on it? Yes, let's wait and see what the company has to say about it.

[alphorn] 21/7/2018 13:07

He certainly plays musical chairs!

[pugugly] 21/7/2018 12:57

Edited after a background search. IMO GSK could have done themselves a better if they had given the dates when he was at previous companies.

See history link


As are rported on the GSK site. Prior to joining GSK, Sir Philip chaired major FTSE 100 companies, including The Royal Bank of Scotland Group plc and J Sainsbury plc. He has also served as Group Finance Director at Lloyds TSB Group, BT Group plc, BG Group plc, British Gas plc and British Steel plc. Sir Philip was previously appointed an Executive Director of Lazards and a Non-Executive Director at RMC Group Plc and Belgacom SA. Until 2009, he was Chairman of UK Financial Investments Limited, which manages the UK Government’s shareholdings in banks.

Looks more like an accountant bailed in to trouble shoot and break-up some companies BUT no pharma or FMCG background - while a breakup of GSK might give short term profits (or recovery of losses to some still holding from the £20 days) it is likely to make the invidual parts more liable to foreign takeovers -
Not the sort of man many would want to hoist a for sale sign over one of the few reamaining UK global leaders.

[ianood] 21/7/2018 12:27

Haven't seen anything lately on the mooted sale of Horlicks?

[alphorn] 21/7/2018 12:19

A split may bring money short term but in terms of strategy the questions needs to be asked about the impact on the eeking out IP by moving prescription only drugs into the OTC market (eg Voltaren - diclofenac). Even the new toothpastes have some smart actives.
If they go ahead it depends of course where the line is drawn.

[alphorn] 21/7/2018 11:52

Richard XII #696. Yes, I don't know what the Chairman is doing. An apparent overruling of the CEO is like a vote of no confidence. Unless the picture is cleared very quickly she has been undermined.


Wait until Monday when there will have to be an RNS. That clarification will be the share price driver.

[mattboxy] 21/7/2018 11:40

Woodford always wanted a split into 3 companies HealthcareHIVVACCINESHe sold out because they wouldn't maybe now they willAlways thought the defensive side of healthcare protects from the risks of drug discovery

[tradermichael] 21/7/2018 11:09

Well said.

[pugugly] 21/7/2018 10:35

Pharma is very volatile with patent cliffs and phase 3 failures - Great is all phase 3 successes but very unlikely.
Consumer HealthCare including the residual toiletry lines particularly dentifrice a reliable cash cow to support pharma through lean periods
Why change a successful model for a higher risk strategy just to appease a few short term hedgies

[tradermichael] 21/7/2018 10:22

Any announcement would surely elevate the price by more than 3 or 4 percent - any other suggestions as to the value of the 'sum of the parts'??

[richard xii] 21/7/2018 00:19

The announcement may move the share price up by three or four per cent.The problem I have with the move is that Hampton appears to be overruling Emma Walmsley who is the CEO. Any reorganisation is her responsibility, not the chairman's. British boards normally appoint third rate CEOs on high salaries who do little or nothing to improve the company.Emma Walmsley seems to be competent at running consumer products, pharma and vaccines and has quickly moved to shake up the management at GSK. But the job has only just started.Adding a reorganisation on top of all that against her will seems an unwelcome distraction. It is sort of like new UK governments who always decide to reorganise the NHS. It takes all the attention of the senior people and the secretary of state all for little benefit and often takes things backwards as morale declines further and actual health care deteriorates.

[scottishfield] 20/7/2018 22:19

Interesting, nice jump on the NYSE

[solomon] 20/7/2018 21:46

Almost 5x average volume on the ADR's
Could be a flash in the pan but Financial Times is cited as the source.